Large-scale trial demonstrates improved detection and therapy monitoring of gliomas, suggesting better outcomes through multistage validation.
µPerf improves early detection of glioma recurrence and shows a higher sensitivity of microvascular changes compared with cMRI. µPerf has significant potential to promote more timely and personalized treatment strategies, which, in turn, could improve patient outcomes. Notably, µPerf works with standard clinical follow-up protocols, but its integration into clinical practice requires further validation through multicenter studies and long-term outcome analyses.
No takes yet. Share an insight, caveat, or question.
Stefan Oberndorfer (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: